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Drug screena b s t r a c t
With emerging resistance to frontline treatments, it is vital that new drugs are identified to target
Plasmodium falciparum. One of the most critical processes during parasites asexual lifecycle is the inva-
sion and subsequent egress of red blood cells (RBCs). Many unique parasite ligands, receptors and
enzymes are employed during egress and invasion that are essential for parasite proliferation and sur-
vival, therefore making these processes druggable targets. To identify potential inhibitors of egress and
invasion, we screened the Medicines for Malaria Venture Pathogen Box, a 400 compound library against
neglected tropical diseases, including 125 with antimalarial activity. For this screen, we utilised trans-
genic parasites expressing a bioluminescent reporter, nanoluciferase (Nluc), to measure inhibition of par-
asite egress and invasion in the presence of the Pathogen Box compounds. At a concentration of 2 mM, we
found 15 compounds that inhibited parasite egress by >40% and 24 invasion-specific compounds that
inhibited invasion by >90%. We further characterised 11 of these inhibitors through cell-based assays
and live cell microscopy, and found two compounds that inhibited merozoite maturation in schizonts,
one compound that inhibited merozoite egress, one compound that directly inhibited parasite invasion
and one compound that slowed down invasion and arrested ring formation. The remaining compounds
were general growth inhibitors that acted during the egress and invasion phase of the cell cycle. We
found the sulfonylpiperazine, MMV020291, to be the most invasion-specific inhibitor, blocking successful
merozoite internalisation within human RBCs and having no substantial effect on other stages of the cell
cycle. This has significant implications for the possible development of an invasion-specific inhibitor as
an antimalarial in a combination based therapy, in addition to being a useful tool for studying the biology
of the invading parasite.
 2020 The Author(s). Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Malaria remains a significant global health burden with an esti-
mated 228 million cases worldwide in 2018, resulting in 405,000
deaths (World Health Organization, 2019). Of the Plasmodium
spp. known to infect humans, Plasmodium falciparum remains the
deadliest and is therefore a focus in the fight to eradicate malaria.There is emerging resistance of P. falciparum to the gold standard
artemisinin combination therapies (ACTs) whereby delayed para-
site clearance has been observed in regions of southeastern Asia
(Dondorp et al., 2009; Fairhurst and Dondorp, 2016; Vijaykadga
et al., 2006; World Health Organization, 2019). With the spread
of resistance to artemisinin and its partner drugs, it is vital that
novel therapeutics are developed and ready to deploy when ACTs
are rendered ineffective.
The red blood cell (RBC) stage of infection causes the clinical
symptoms of malaria. Asexual blood stage parasites progress
through a series of developmental phases that begin with the intra-
cellular ring stage, followed by the trophozoite stage and concludes
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approximately 20 invasive merozoites egress from the nutrient-
deprived infected RBC (iRBC) after the breakdown of the para-
sitophorous vacuole membrane (PVM), followed by the rupture
of the RBC membrane (Wickham et al., 2003; Chandramohanadas
et al., 2011). Egress appears to be initiated via the activation of
cGMP dependent protein kinase G (PKG), which has been shown
to be specifically inhibited by the trisubstituted pyrrole, Com-
pound 1 (C1) (Gurnett et al., 2002; Taylor et al., 2010; Hopp
et al., 2012). Activated PKG triggers the discharge of the serine
subtilisin-like protease (SUB1) from the exonemes (Yeoh et al.,
2007; Collins et al., 2013) that undergoes autoprocessing in the
endoplasmic reticulum (ER) (Blackman et al., 1998; Sajid et al.,
2000), followed by a second processing event, requiring the aspar-
tic protease, plasmepsin X (PMX) (Nasamu et al., 2017; Pino et al.,
2017). Secretion of mature SUB1 into the parasitophorous vacuole
(PV) induces the processing of serine rich antigen 5 and 6 proteins
(SERA5/6) (Yeoh et al., 2007; Ruecker et al., 2012; Collins et al.,
2013; Collins et al., 2017; Thomas et al., 2018), merozoite surface
protein 1 (MSP1) (Das et al., 2015), as well as other merozoite sur-
face proteins (Koussis et al., 2009; Silmon de Monerri et al., 2011).
Permeabilisation of the PVM occurs 10–30 min prior to PKG activa-
tion of SUB1, indicating that there are other unknown effector
molecules required for PVM fragmentation (Hale et al., 2017). Both
SUB1-activated SERA6 and MSP1 have both been implicated in dis-
rupting the RBC membrane to allow egress of merozoites via cleav-
age and binding of spectrin within RBCs, respectively (Das et al.,
2015; Thomas et al., 2018). Furthermore, a conditional knockdown
of SERA6 elucidated a similar phenotype to the cysteine protease
inhibitor, E64, whereby PVM rupture occurred but the RBC mem-
brane remained intact (Glushakova et al., 2009; Thomas et al.,
2018). Other regulatory enzymes such as calcium dependent
kinases 1 and 5 (CDPK1/5) have also been implicated as important
mediators of signalling cascades to allow merozoite egress (Dvorin
et al., 2010; Iyer et al., 2018). Recently, it has been shown that
CDPK5 is required for the discharge of micronemes and may be
involved in a partnership with PKG to ‘enhance’ the cascade of
events that eventuate in the release of invasive merozoites
(Absalon et al., 2018). Following egress, the merozoite secretes pro-
teins from its unique secretory organelles; the rhoptries and
micronemes, which enable the merozoite to invade new RBCs in
a complex multi-step process that is still not fully understood
(Sam-Yellowe, 1996; Bannister et al., 2000; Farrow et al., 2011).
The primary contact between a merozoite and a RBC occurs via a
multi-protein complex containing MSP1 (Holder and Freeman,
1984; Lin et al., 2014) and possibly heparin sulfate proteoglycan
receptors on the RBC surface, since heparin inhibits this interaction
(Vogt et al., 2004; Boyle et al., 2017). Subsequent stronger attach-
ment between merozoites and RBCs is through the binding of
merozoite proteins, namely, reticulocyte binding like homologs
(Rhs) and erythrocyte binding proteins (EBAs), which are secreted
from the rhoptries and micronemes, respectively (Camus and
Hadley, 1985; Mayer et al., 2001; Lanzillotti and Coetzer, 2006;
Li et al., 2012). Downstream binding of Rh5 to the RBC receptor,
basigin, then possibly activates the secretion of the rhoptry neck
protein complex (RON) which becomes embedded into the RBC
surface (Weiss et al., 2015). Here, RON2 interacts with apical mem-
brane antigen 1 (AMA1) which is secreted from the micronemes
onto the merozoite surface, leading to the formation of a tight
junction between the invading merozoite and RBC (Cao et al.,
2009; Lamarque et al., 2011). The parasite’s actin-myosin motor
applies a penetrative force to propel the merozoite into the RBC,
during which the merozoite envelops itself in the RBC membrane,
forming the PVM (Dobrowolski and Sibley, 1996; Gonzalez et al.,
2009). Less than 1 min after invasion, the RBC undergoes echinocy-
tosis, a morphological change from its normal biconcave shape to astellate form, hypothesised to be caused by an efflux of ions or a
disruption to the phospholipid bilayer of the RBC upon secretion
of rhoptry proteins (Gilson and Crabb, 2009; Weiss et al., 2015;
Weiss et al., 2016). Since many of the protein–protein interactions,
signalling cascades and enzymes required for egress and invasion
are unique to parasites, they could represent novel drug targets
that may be effective antimalarials when used in combination with
drugs that act during the intraerythrocytic stage (reviewed in
(Burns et al., 2019)).
To facilitate open source drug discovery for antimalarials,
Medicines for Malaria Venture (MMV) has released a series of
small compound libraries, screened for their ability to inhibit the
RBC stage of the parasite’s lifecycle (http://www.mmv.org/re-
search-development). The first compound library, termed the
Malaria Box (Van Voorhis et al., 2016), was phenotypically
screened by Subramanian et al. (2018) for blood stage egress and
invasion inhibitors which resulted in the identification of 26 com-
pounds that inhibited schizont to ring transition by greater than
50% (Subramanian et al., 2018). The second generation library
released by MMV was labelled the Pathogen Box, and it contains
400 compounds against neglected tropical diseases, 125 from the
Malaria disease set and 15 with activity against the related para-
site, Toxoplasma gondii. To date, the Pathogen Box has been a useful
tool in high throughput screens (HTS), with many compounds
identified as inhibitors of a variety of disease causing organisms
(Duffy et al., 2017; Hennessey et al., 2018; Spalenka et al., 2018;
Tong et al., 2018; Nugraha et al., 2019; Nyagwange et al., 2019;
Wang et al., 2019). We have screened the Pathogen Box using a
bioluminescent semi-high throughput system to identify inhibitors
of RBC egress and invasion, identifying 15 and 24 inhibitors,
respectively, with these properties. After removing compounds
with known, non-invasion related targets or those that did not
inhibit parasite growth, we performed a detailed analysis of 11 of
these compounds by studying their effects upon egress and
invasion.2. Materials and methods
2.1. Parasite culture and strains
Plasmodium falciparum parasites were continuously cultured as
previously described (Trager and Jensen, 1976) in human RBCs
(Australian Red Cross Blood Bank, Type O) at 4% haematocrit in
supplemented RPMI medium (RPMI (Sigma, UK), HEPES (GIBCO,
USA), 0.2% NaHC03 (Thermo Scientific, Australia), 5% heat-
inactivated human serum (Australian Red Cross), 0.25% AlbumaxII
(GIBCO, New Zealand), 0.37 mM hypoxanthine (Sigma, USA),
31.25 mg/mL of Gentamicin (GIBCO, USA)) at 37 C. An exported
Nluc parasite line (PEXEL-Nluc) was used as previously described
(Azevedo et al., 2014), which was generated by transfecting a
Hyp1-Nluc plasmid under the control of an ef1a promoter into
3D7 P. falciparum parasites (Hasenkamp et al., 2012). Uptake of
the plasmid was selected for and maintained by 2.5 nM
WR99210 (Jacobus, USA). This parasite line was used for all exper-
iments in the study.2.2. Compounds
Pathogen Box compounds were obtained from MMV and con-
sisted of 400 compounds at 10 mM dissolved in DMSO (https://
www.pathogenbox.org/). Compounds were diluted to 100 mM
and aliquoted into 96 well plates at 80 C for long-term storage.
The compounds were then diluted to a final concentration of 2 lM
in RPMI medium for the screen and early ring inhibition assay,
with a final concentration of 0.02% DMSO. Further quantities of
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MMV688279, MMV676877 and MMV676881 were provided by
MMV and MMV016838 (MolPort-001-614-591), MMV020512
(MolPort-004-158-754), MMV019721 (MolPort-004-102-322) and
MMV687794 (MolPort-002-553-011) were purchased from Mol-
port. R1 peptide (a kind gift from Alan Cowman, Walter and Eliza
Hall Institute, Australia) and porcine heparin (Sigma, USA) were
dissolved in RPMI medium. Chloroquine (Sigma, USA) and E64
(Sigma, USA) were dissolved in water. Artemisinin (Sigma, USA)
and Compound 1 (custom made) and all other compounds were
dissolved in DMSO. In all experiments, heparin was used at
100 lg/mL (Boyle et al., 2010a), Compound 1 at 4 lM (10  EC50
of egress as determined in Supplementary Fig. S1A) and E64 at
10 lM (Glushakova et al., 2009). In order to minimise non-
specific invasion or egress inhibition due to potency, antimalarials
chloroquine and artemisinin were used at 5  EC50 of growth
which corresponded to 75 nM and 15 nM, respectively.
2.3. Nanoluciferase invasion assay and statistical validation for a high
throughput screen
Parasites were grown to late stage schizonts and isolated using
a Percoll density gradient whereby culture was added to 60% buf-
fered Percoll solution in supplemented RPMI (10 mM NaH2PO4,
143 mM NaCl, Percoll (GE Healthcare Bio-Sciences, Sweden)). Puri-
fied schizonts at 1–2% parasitemia were added to RBCs with a final
haematocrit of 1%. Drugs were administered at concentrations of
0.02%, 4 mM and 100 mg/mL for DMSO, C1 and heparin, respec-
tively. Plates were incubated at 37 C for 4 h and the growth med-
ium was removed to measure Nluc released upon merozoite egress
(see section 2.4). This time frame was chosen as it allowed suffi-
cient egress and invasion events to occur and produce a robust
invasion signal, whilst minimising the exposure time of newly
invaded ring-stage parasites to the inhibitors that could produce
false positives for invasion inhibition. Cells were treated with sor-
bitol to induce osmotic lysis of remaining schizonts, and three
washes were performed before incubating the culture at 37 C
for a further 24 h until parasites were >24 h post invasion. Whole
cells were lysed to measure intracellular Nluc, corresponding with
initial invasion rate (see Section 2.4). A background control was
included for the egress measurements which consisted of the
growth media of Percoll purified cultures that had been kept at
4 C during the first 4 h incubation period. This allowed a baseline
level of Nluc to be established to ensure the signal measured was
attributed to schizont rupture and not spontaneous lysis or cell
leakage. To account for contamination of ring stage parasites that
failed to be removed from Percoll gradient and schizonts that
failed to be removed by sorbitol treatment, a background control
for the invasion measurements was included whereby Percoll
purified cultures were kept at 4 C during the first 4 h incubation
and subsequently treated with sorbitol before further incubation
at 37 C for 24 h.2.4. Measuring nanoluciferase activity
Whole cells (5 mL) at 1% hematocrit (invasion) or growth med-
ium (egress) were dispensed into white 96 well luminometer
plates and 45 mL of 1  NanoGlo Lysis Buffer containing 1:1000
NanoGlo substrate (Promega, USA) was injected into wells. Relative
light units (RLU) was measured by a CLARIOstar luminometer
(BMG Labtech).
2.4.1. Analysis
The percent of invasion/egress was determined as described in
the formula below:Invasion or Egress %ð Þ
¼ ðRLUAV Treated  RLUAV background control egress or invasionð ÞÞðRLUAV UT  RLUAV background control egress or invasionð ÞÞ X100
The mean and S.D. of 60 total wells (15 wells per plate over four
biological replicates) for each drug treatment was used to calculate
Z factors. DMSO, heparin and C1 treatments were first normalised
to the untreated control and values were input into the following
equation as per (Zhang et al., 1999):
Z ¼ 1 3S:D:Heparin=C1 þ 3S:D:DMSO
absðmeanHeparin=C1 meanDMSOÞ2.5. Screening the Pathogen Box
The Nanoluciferase invasion assay was used as described above.
Pathogen Box compounds were diluted to a final concentration of
2 mMwith concentrations of DMSO, C1 and heparin as listed above.
Chloroquine was included at 75 nM. Each plate contained 40 com-
pounds in duplicate with control compounds. The percentage of
invasion and egress in the presence of compounds was normalised
relative to the mean of DMSO (100% egress or invasion rate) that
was averaged across three biological replicates.2.6. Counter screen
Parasites were grown to 24 h post invasion and adjusted to a
final haematocrit of 1% with 1–2% parasitemia. Cells were lysed
in 1 Nanoglo Lysis Buffer (Promega) and lysate was added to
10 mM of the Pathogen Box compounds and incubated for 10 min
at 37 C. Nanoluciferase activity was measured as above with
45 mL of lysate dispensed into 96 well white luminometer plates
and 5 mL of 1:100 NanoGlo substrate injected into wells. Nluc activ-
ity in presence of compounds was normalised relative to 0.1%
DMSO (100% Nluc activity).2.7. Early ring inhibition assay
This was performed as per the Nluc invasion assay with Patho-
gen Box compounds tested at a concentration of 2 mM. Chloroquine
and artemisinin were included at concentrations of 75 nM and
25 nM, respectively. Duplicate wells for each compound were set
up, one that received drug treatment during the egress/invasion
window and one that remained untreated. After the 4 h incubation,
following sorbitol treatment and washes, the well that was
untreated received drug treatment for a further 4 h before being
washed three times. At 24 h post invasion, cultures were lysed
and Nluc activity measured as described above. Percentage of inva-
sion and early ring growth in the presence of compounds was nor-
malised relative to 0.02% DMSO (100% invasion or early ring
growth).2.8. Egress inhibition reversibility assay
Schizonts were Percoll purified as described above and cultured
in 1% haematocrit of 1–2% parasitemia. To this, C1, MMV011765,
MMV016838 and DMSO were added at final concentrations of
4 mM, 10 mM, 10 mM and 0.1%, respectively. Plates were incubated
for 2 h at 37 C before growth medium was collected. Pellets were
washed three times and incubated for a further 4 h at 37 C before
growth medium was collected. Nluc released in the growth med-
ium was measured as described above. Egress was normalised rel-
ative to 0.1% DMSO after 2 h and normalised to cumulative 0.1%
DMSO after 4 h (i.e. 2 h + 4 h DMSO RLU).
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Adapted from (Boyle et al., 2010b; Wilson et al., 2013, 2015)
where parasites were grown to schizonts, magnet purified and
treated with 10 mM E64 (or 10 mM MMV676881) for 4–6 h until
>50% had become RBC membrane (RBCM) trapped merozoites.
Schizonts were washed with supplemented RPMI before being
mechanically disrupted by passage through a 1.2 mm filter and
distributed into a 96-well plate with a final hematocrit of 1%
and ~10  EC50 of growth of each drug (10 mM MMV020291,
3 mM MMV006833, 3 mM MMV668279, 7 mM MMV676877, 3 mM
MMV687794, 5 mM MMV020512, 5 mM MMV019721, 10 mM
MMV637229 (5  EC50)). The 96-well plate was shaken at
400 rpm for 30 min at 37 C. Pellets were washed three times
and put back into culture for 24 h before Nluc activity was mea-
sured as described above. Invasion was normalised relative to
0.1% DMSO.
2.10. Trophozoite growth assays
Hyp1-Nluc parasites at ~24 h post invasion were adjusted to 1%
parasitemia and 1% haematocrit in a 96-well plate before being
exposed to 10  EC50 of Pathogen Box compounds for 4 h. Plates
were then washed three times in supplemented RPMI before being
put back into culture until the following cycle. Growth was calcu-
lated at ~24 h post invasion by measuring Nluc activity as
described above. C1, heparin, chloroquine and artemisinin were
included as controls at 4 mM, 100 mg/mL, 75 nM and 25 nM, respec-
tively. Values were normalised to 0.1% DMSO as a vehicle control.
2.11. Determination of EC50s for parasite invasion and egress of RBCs
Compounds were serially diluted from 10 mM and rates of par-
asite egress and invasion were measured by the Nluc invasion
assay as described above. Percentage of invasion and egress in
the presence of compounds was normalised to 0.1% DMSO (100%
invasion or egress rate). Curves were then normalised between 0
and 100%. EC50 curves were generated from GraphPad Prism using
a non-linear regression.
2.12. Live cell microscopy
Live cell microscopy was performed as described in Crick et al.
(2013) and Weiss et al. (2015) on a Zeiss Cell Observer widefield
fluorescent microscope equipped with a humidified gas chamber
(1% O2, 5% CO2 and 94% N2) at 37 C. Eight well LabTek chambered
slides were filled with 200 mL of parasite culture, diluted to a final
0.1% haematocrit in RPMI medium and treated with 10  EC50 of
compound. Mature schizonts that appeared to rupture were
imaged at two to four frames per s using the AxioCam 702 Mono
camera for 20 min. Image and data analysis of cell behaviour was
performed using ImageJ and GraphPad Prism with statistical tests
between treated and vehicle control including unpaired t tests
(for normally distributed data) and Mann-Whitney t test (for
non-normally distributed data).
2.13. Bodipy staining
RBCs at 1% haematocrit were stained with bodipy sphin-
gomyelin green (Life Technologies, Australia) diluted 1:500 in
RPMI by incubating overnight at 37 C. Trophozoites were incu-
bated with 1:1000 bodipy ceramide Texas red (Life Technologies,
Australia) overnight in RPMI as described above but without
human serum and decreased Albumax (0.125%). Approximately
12 h later, schizonts were Percoll purified as described above and
stained RBCs were washed twice in RPMI. Schizonts and RBCs werecombined and then imaged as described above for live cell micro-
scopy conditions.3. Results
3.1. Development and validation of bioluminescent egress and
invasion screening assay
To screen the MMV Pathogen Box for egress and invasion
inhibitors, we used P. falciparum 3D7 parasites expressing a
Nanoluciferase (Nluc) that is exported into the cytoplasmic com-
partment of the iRBC (previously described in Azevedo et al.
(2014)) in an assay we termed the Nluc invasion assay (Fig. 1A).
Briefly, in this assay late stage schizonts were purified and added
to RBCs in the presence of inhibitors for 4 h. The culture medium
was then collected to measure bioluminescence in RLU of the Nluc
released upon schizont rupture. The iRBCs were then treated with
5% isotonic sorbitol to lyse remaining schizonts, leaving intact
newly invaded ring stage parasites. Since it was not possible to
measure Nluc in the new ring stage parasites as Nluc expression
was too low (Azevedo et al., 2014), the iRBCs were grown for
~24 h until trophozoites (parasite age range 24–28 h post inva-
sion). The trophozoite iRBCs were then lysed and degree of inva-
sion was inferred by RLU levels.
To validate the suitability of this assay for HTS, we generated Z-
factors using the well-characterised egress and invasion inhibitors,
C1 and heparin, respectively, as positive controls for inhibition of
egress and invasion, respectively (Zhang et al., 1999; Gurnett
et al., 2002; Hopp et al., 2012; Weiss et al., 2015; Boyle et al.,
2017). For both egress and invasion, the assay achieved moderate
separation bands between its positive (C1 and heparin) and nega-
tive drug vehicle DMSO control, producing Z-factors for egress and
invasion of 0.39 and 0.49, respectively (Fig. 1B). Whilst the ideal Z-
factor for an assay to be used in a HTS is >0.5, the Z-factors we
achieved in the Nluc invasion assay were on the threshold to dis-
tinguish positive from negative hit compounds. However, due to
the small size of the Pathogen Box, we felt that it was an acceptable
method to use as we could conduct follow-up assays to identify
non-specific inhibitors. C1, heparin and R1 peptide, which blocks
the interaction between AMA1 and RON2 (Harris et al., 2005;
Richard et al., 2010), were also tested at multiple concentrations
in the Nluc invasion assay which produced dose–response curves
from which we could derive the half maximal effective concentra-
tion (EC50) for egress and invasion (Supplementary Fig. S1). It
should be noted that egress inhibitors, similar to C1, also inhibit
invasion in this assay because the merozoites are unable to escape
the iRBC (Fig. 1A).3.2. A screen of the Pathogen Box compounds reveals many egress and
invasion inhibitory compounds
The Pathogen Box compounds were screened at 2 mM for inva-
sion and egress inhibition using the Nluc invasion assay. Based on
control compound activity in the Z-factor assays, cut-offs for posi-
tive hits of egress inhibition were set at reducing egress to <60%
and cut-offs for positive hits of invasion inhibition were set at
reducing invasion to <10% (assuming vehicle control has 100%
egress/invasion rates). From the screen, we found 15 compounds
that reduced egress to <60% and 36 compounds that reduced inva-
sion to <10% when normalised to DMSO at 100% (Fig. 1C and Sup-
plementary Table S1). The hits from the Nluc screen then
underwent a compound triaging process to identify compounds
that were to be investigated further (Tables 1 and 2). Of the 15
compounds that inhibited egress, MMV688274 was removed since
a counter screen performed with parasite lysate indicated the com-
Fig. 1. Plasmodium falciparum blood stage parasites expressing an exported nanoluciferase reporter protein enables the quantification of egress and invasion and identified
inhibitors of these processes in the Medicines for Malaria Venture Pathogen Box. (A) Schematic of the nanoluciferase (Nluc) invasion assay set-up whereby purified late
schizonts expressing an exported Nluc were treated with compounds for 4 h. Egress inhibitors, such as Compound 1 (C1), prevent release of Nluc which was detected when
the bioluminescence of the growth medium was measured after 4 h incubation. The infected red blood cells (RBCs) were then treated with 5% sorbitol to lyse schizonts,
leaving newly infected ring-stage parasites behind. The ring-stage parasites were grown until trophozoites when they were lysed and their total Nluc levels measured to infer
the degree of invasion. The invasion inhibitor, heparin, was used as a control compound. (B) Egress (i) and invasion (ii) of Nluc parasites following a 4 h treatment with
compound vehicle DMSO, C1 or heparin that were used at concentrations of 0.02%, 4 lM and 100 lg/mL, respectively. (i) The Z-factor of 0.39 for C1 demonstrates a moderate
separation band between positive and negative controls. (ii) For parasite invasion, both C1 and heparin were used as positive controls which was reflected in their Z-factors of
0.47 and 0.49, respectively. Values have been normalised and expressed as a percentage of untreated (UT) parasites. Sixty replicates were performed for each condition over
three independent experiments. Z indicates Z-factor. (C) Using the Nluc egress/invasion assay, the Pathogen Box compounds were screened at 2 mM and it was found that 15
compounds reduced egress rate <60% (i) and 36 compounds reduced invasion rate <10% (ii). All values have been normalised to compound vehicle DMSO. Each dot represents
the mean of a compound from three biological replicates. Dotted lines indicate cut-off values of 60% and 10% for egress and invasion inhibition, respectively. Positive control
compounds, heparin and C1, were used at 100 mg/mL and 4 mM, respectively. Chloroquine (CQ) was included as a negative control at 75 nM and DMSO vehicle control was
used at 0.02%.
M.G. Dans et al. / International Journal for Parasitology 50 (2020) 235–252 239pound inhibited Nluc activity (Supplementary Fig. S2, Table 1).
Due to the design of the Nluc invasion assay, inhibitors of early
ring-stage parasites (0–4 h post invasion) could be exposed to
the parasites for up to 4 h, resulting in false positives for invasioninhibition (Fig. 1A). As such, compounds were tested for early ring
stage growth inhibition activity and this resulted in the removal of
one of the egress hit compounds, MMV667494, leaving a remain-
ing 13 compounds targeting egress (astericks, Fig. 2A, Table 1).
Table 1
A nanoluciferase (Nluc) screen identified 15 Pathogen Box compounds as egress hits of Plasmodium falciparum.
aEgress and invasion data derived from Nluc invasion screen representing the mean of three biological replicates performed at 2 mM (Fig. 1c).
bNluc activity values represent the mean of two biological replicates in a counter screen performed at 10 mM to identify inhibitors of Nluc (Supplementary Fig. S2).
cEC50 for growth data derived from Medicines for Malaria Venture (MMV; *) or Duffy et al. (2017) (#).
dRing growth values demonstrate the mean of three biological replicates performed at 2 mMwhich identified compounds that inhibit early ring-stage parasite growth (Fig. 2).
ePossible mechanisms of action (MoA) (Dennis et al., 20181; Zhang et al., 20062; Crowther et al., 20163, Baragaña et al., 20154; Baragaña et al., 20169).
fEC50 for invasion and egress determined by Nluc invasion assay. C.I., 95% confidence intervals for EC50 values Supplementary Fig. S4.
gMMV0168383 was not eliminated as a PfEF2 inhibitor as it did not demonstrate early ring-stage inhibition.
Grey shading represents hits eliminated in the compound triaging process whilst compounds highlighted in yellow were sourced to study further.
N.D., not determined.
240 M.G. Dans et al. / International Journal for Parasitology 50 (2020) 235–252Since we were interested in studying compounds with novel egress
targets, we further triaged our list of egress inhibitors to remove
compounds with known targets and mechanisms of action. One
of these was compound MMV688703 which was found to be struc-
turally identical to C1 and included in the Pathogen Box as it tar-
geted T. gondii PKG (Table 1) (Zhang et al., 2006). MMV030734
was also excluded since it acted upon P. falciparum CDPK1
(PfCDPK1) (Crowther et al., 2016), known to be involved in micro-
neme secretion and activation of the actin-myosin motor (Table 1)
(Bansal et al., 2013; Green et al., 2016). Six compounds which
likely target PfATP4 were also removed since PfATP4 is involved
in the efflux of excess Na+ from the parasite’s cytoplasm and is
therefore unlikely to be directly involved in egress or invasion
which we confirmed using a purified merozoite invasion assay
with the known PfATP4 inhibitor, cipargamin (Table 1, Supplemen-
tary Fig. S3A) (Spillman and Kirk, 2015; Dennis et al., 2018).
MMV016838 was found to be the parent compound of an anti-
malarial in clinical development, M5717, that targets elongationfactor 2 (PfEF2) (Baragaña et al., 2015; Ashley and Phyo, 2018).
However, as MMV016838 did not inhibit ring stage parasites sim-
ilar to other PfEF2 inhibitors in the Pathogen Box that were hits in
our screen (MMV667494 and MMV634140 (Baragaña et al., 2016)),
this compound was not removed. Two additional compounds from
the tuberculosis disease set were also excluded because they
exhibited no antimalarial activity in the P. falciparum blood stage
that had been previously performed by Duffy et al. (2017) (Table 1).
This left three compounds, MMV011765, MMV016838 and
MMV019993 of which we were able to obtain additional quantities
of the first two compounds from commercial sources and MMV to
further study.
Of the 36 compounds which reduced invasion to <10%, 12 of
these were also inhibitors of egress and were subsequently
removed, leaving a remaining 24 invasion-specific inhibitory com-
pounds (Table 2). Two reference compounds (mefloquine
(MMV000016) and pentamidine (MMV000062)) were also
excluded. The invasion hits were also tested for their early ring
Table 2
A nanoluciferase (Nluc) screen revealed 24 Pathogen Box compounds as invasion-specific hits of Plasmodium falciparum.
aInvasion data derived from Nluc invasion screen representing the mean of three biological replicates performed at 2 mM (Fig. 1c).
bNluc activity values represent the mean of two biological replicates performed at 10 mM in a counter screen to identify inhibitors of Nluc (Supplementary Fig. S2).
cEC50 for growth data derived from Medicines for Malaria Venture (MMV; *) or Duffy et al. (2017) (#).
dRing growth values demonstrate the mean of three biological replicates performed at 2 mM which identified compounds that inhibit early ring parasite growth (Fig. 2).
ePossible mechanisms of action (MoA) (Dennis et al., 20181; Younis et al., 20125; Paquet et al., 20176; Le Manach et al., 20167; Duffy et al., 20178; Baragaña et al., 20169;
Rodríguez et al., 200810; Mott et al., 201011; Veale, 201912).
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fEC50 for invasion determined by Nluc invasion assay. C.I., 95% confidence intervals for EC50 values Supplementary Fig. S4.
TMMV676881 identified in the screen as invasion inhibitor was found to be an egress inhibitor upon further characterisation.
Grey shading represents hits eliminated in the compound triaging process whilst compounds highlighted in yellow were sourced to study further.
N.D., not determined; N/A, not applicable; UND, undefined.
Fig. 2. Multiple egress and invasion inhibitors also target the early Plasmodium falciparum ring stage of intracellular growth. The lead compounds from the egress screen (A)
and the invasion screen (B) were assessed for their ability to inhibit early ring parasites (4–8 h post invasion) at a concentration of 2 mM in the Nluc invasion assay. One
compound from the egress screen and six compounds from the invasion screen potently inhibited ring stage parasites (*). Artemisinin (ART) was included as a positive control
for ring stage inhibition at a concentration of 25 nM, and negative controls were chloroquine (CQ), compound 1 (C1) and heparin which were used at concentrations of 75 nM,
4 mM and 100 mg/mL, respectively. Values were normalised to DMSO at a concentration of 0.02%. Dotted line indicates 20% cut-off for early ring stage inhibitors. Error bars
represent the S.D. of three biological replicates.
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six compounds (MMV023969, MMV024311, MMV688362,
MMV024035, MMV023233, MMV634140) (asterisks, Fig. 2B and
Table 2). Compounds targeting PI4K, the mitochondrial cyto-
chrome bc1 complex, DNA machinery, PfEF2 and PfATP4 were
removed since their protein targets have likely non-invasion
related roles (Table 2) (Rodríguez et al., 2008; Younis et al.,
2012; Baragaña et al., 2016; Le Manach et al., 2016; Duffy et al.,
2017; Paquet et al., 2017; Dennis et al., 2018). This left nine com-
pounds targeting invasion which we were able to obtain supple-mentary amounts of from commercial sources or MMV to
conduct phenotypic analyses.3.3. Categorising egress and invasion inhibitory compounds
To identify the phenotypes of these invasion and egress inhibi-
tors, Giemsa-stained blood smears were examined from schizonts
that had been treated for 4 h with 2 mM of the hit compounds
(Fig. 3, Supplementary Table S2). It was found that the egress
Fig. 3. Giemsa stained thin blood smears of Plasmodium falciparum parasites following treatment with lead egress and invasion-inhibitory compounds. Depicted are two early
egress inhibitory compounds, one late egress inhibitor and six compounds with invasion inhibitory activity. Giemsa-stained smears following a 4 h treatment of schizonts
with 2 mM of Pathogen Box compounds (or 20 mM, MMV016838) were used to categorise the lead compounds into either early egress inhibitors (A), late egress inhibitors (B),
invasion inhibitors (C) or undetermined (D). Vehicle control indicates schizonts treated with 0.1% DMSO.
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when the merozoites had formed but had not yet physically sepa-
rated possibly due to an intact PVM (Fig. 3A). The egress inhibitor,
MMV016838 did not appear to inhibit egress or invasion at 2 mM
compared with vehicle control. Therefore, the concentration was
increased to 20 mM (10  EC50 of egress, Supplementary
Fig. S4Ai) upon which a similar inhibition of schizont/merozoite
maturation phenotype to MMV011765 and C1 was observed
(Fig. 3A). Based on the Nluc screen, MMV676881 was predicted
to be an invasion inhibitor, however Giemsa stained smears indi-
cated that MMV676881 prevented merozoite egress, probably after
breakdown of the PVM but not the RBC membrane since the mero-
zoites appeared physically separated within the schizont (Fig. 3B).
Of the remaining eight invasion inhibitors identified in the
screen, six (MMV676877, MMV006833, MMV637229,
MMV020291, MMV688279, MMV687794) demonstrated a degree
of invasion inhibitory activity by Giemsa stained smears since
fewer rings were observed than in the DMSO vehicle control (Sup-
plementary Table S2). In agreement with this, there were more
merozoites counted (free and collocated with RBCs) in proportion
to DMSO, (Fig. 3C, Supplementary Table S2). The remaining two
compounds identified as invasion inhibitors from the screen
(MMV019721 and MMV020512) had inconclusive phenotypes
whereby MMV020512 treatment did not increase the proportion
of merozoite or decrease the proportion of schizonts, relative toDMSO (Supplementary Table S2). MMV019721 did increase the
proportion of schizonts relative to DMSO, however a number of
ring stage parasites were also present, making it unclear how the
compound was affecting egress and/or invasion (Fig. 3D).3.4. Egress inhibitors function at two stages of schizont maturation
and do not specifically affect merozoite invasion of RBCs
To further characterise the egress inhibitors, live schizonts were
examined under culture conditions by brightfield microscopy after
4 h of drug treatment. MMV011765 and MMV016838 treatment
revealed they were similar to C1-arrested schizonts where the
merozoites were indistinct from each other, possibly because they
were spatially confined with intact PVM and RBC compartments
(Fig. 4Ai). To test if this inhibition was reversible, schizonts
expressing Nluc were treated with C1, MMV011765 or
MMV016838 for 2 h to arrest egress which was confirmed due to
reduced Nluc activity in the growth medium relative to a DMSO
control (Fig. 4Aii). To measure reversibility, the compounds were
washed out and egress was allowed to proceed for a further 4 h.
Nluc activity in the growth medium indicated egress had resumed
for the reversible inhibitor, C1, and MMV016838 but not for
MMV011765. This indicates that the latter is an irreversible egress
inhibitor, either by irreversibly binding to its target protein to dis-
rupt function or by being resistant to wash-out methods (Fig. 4Aii).
Fig. 4. Treatment of Plasmodium falciparum schizonts with egress inhibitors reveals some compounds are reversible and/or do not specifically inhibit invasion of purified
merozoites. (A) (i) Brightfield microscopy reveals treatment of schizonts with 10 mM MMV011765 and MMV016838 blocks the maturation and separation of merozoites
similar to treatment with 4 mM Compound 1 (C1). (ii) Measurement of egress during and after the removal of inhibitory compounds as determined by the release of
nanoluciferase (Nluc) into the growth medium indicates MMV011765 is an irreversible inhibitor whilst MMV016838 is a reversible inhibitor, similar to C1. Values have been
normalised to 0.1% DMSO with concentrations of Medicines for Malaria Venture compounds at 10 mM and C1 at 4 mM. (B) (i) Live cell microscopy demonstrates that
MMV676881 prevents the release of merozoites, similarly to the protease inhibitor E64 by producing red blood cell (RBC) membrane trapped merozoites. Single frames of
videos are shown in (i) (Supplementary Videos S1, S2) after a 4 h treatment of schizonts with 10 mM MMV676881 and 10 mM E64. (ii) Mechanical rupture of RBC membranes
after 4 h treatment with 10 mM MMV676881 and 10 mM E64 demonstrated the merozoites were viable and invasion competent with exposure to MMV676881 resulting in a
similar degree of invasion as E64-treatment as determined by measurement of Nluc activity 24 h later. Control compound heparin inhibited merozoite invasion of
MMV676881 treated schizonts. A Giemsa stained smear of a trophozoite at 24 h post invasion after MMV676881 schizont treatment showing that merozoites invaded and
progressed to trophozoites normally. All values have been normalised to 10 mM E64. (C) Merozoite invasion assays demonstrate MMV011765, MMV016838 and MMV676881
at 10  EC50 for growth (concentrations in lM specified in brackets or lg/mL for heparin) were specific for egress inhibition with merozoite invasion remaining relatively
unaffected. No significant difference between the Medicines for Malaria Venture compounds and chloroquine (CQ) was seen, in contrast to heparin. Values have been
normalised to 0.1% DMSO. Statistical analysis for (A) (ii) was performed via two-way ANOVA; (B) (ii), unpaired t test; (C), one-way ANOVA using GraphPad Prism. *P < 0.05,
**P < 0.01, ***P < 0.001 and ****P < 0.0001. No bar indicates not significant. Error bars represent the S.D. of three biological replicates.
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zoite invasion after egress had resumed (Supplementary Fig. S5).
Next, schizonts were treated with the later acting MMV676881
and when visualised by brightfield microscopy, RBCM trapped
merozoites were observed, resembling treatment with the cysteineprotease inhibitor, E64 (Fig. 4Bi, Supplementary Videos S1 and S2).
It should be noted that E64 does not prevent Nluc release in the
Nluc invasion assay, similar to MMV676881 (Supplementary
Fig. S3B). To further support MMV676881 acting as an E64-like
inhibitor, a merozoite viability assay was performed whereby puri-
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induce RBCM trapped merozoites, and mechanically broken open
to release merozoites to allow invasion of new RBCs. A negative
control containing heparin was also included to block invasion.
Ring-stage parasites were grown for 24 h and the degree of inva-
sion was inferred by measuring the Nluc activity of the whole cul-
ture. The Nluc activity of trophozoites treated with MMV676881 at
schizonts in the previous cycle was, on average, 108% of those trea-
ted with E64, with heparin reducing invasion to 20% (Fig. 4Bii,
P < 0.0001), demonstrating that both MMV676881 and E64 block
merozoite egress but do not affect the merozoites ability to invade
RBCs. This strengthens support for MMV676881 acting similarly to
an E64-like egress inhibitor by preventing breakdown of RBC
membranes, without affecting merozoite viability.
The three egress inhibitors, MMV011765, MMV016838 and
MMV676881, were also tested for their ability to specifically inhi-
bit merozoite invasion in invasion assays with purified merozoites
(Boyle et al., 2010b; Wilson et al., 2013, 2015). Briefly, purified
schizonts were treated with E64 until the formation of RBCM
trapped merozoites, then mechanically ruptured to release the
merozoites. The merozoites were rapidly added to fresh RBCs in
the presence of 10  EC50 of the compounds and left to invade
the RBCs at 37 C for 30 min. The compounds were then washed
out of the new ring stage parasites and cultured for a further
24 h with quantification of invasion performed by measuring Nluc
activity present in trophozoite iRBCs. This revealed that
MMV011765, MMV016838 and MMV676881 did not affect mero-
zoite invasion of RBCs, with no differences observed between the
egress inhibitors and the antimalarial, chloroquine, which does
not inhibit invasion. In contrast, the control compound heparin
dramatically reduced the degree of RBC invasion (Fig. 4C). Taken
together, these findings indicate that MMV011765, MMV016838
and MMV676881 are inhibitors of merozoite egress at early and
late stages of schizont maturation and do not specifically inhibit
merozoite invasion of RBCs.Fig. 5. MMV020291 is the most specific invasion inhibitory compound. (A) Plasmodiu
inhibitors identified from the screen, MMV020291, is the only compound to directly b
MMV637229, MMV006833 and MMV020512 induce intermediate invasion inhibitory eff
stage parasites after exposure to the lead compounds for 4 h demonstrates that multiple
with MMV688279, causing significant growth reduction when compared with the contro
specified in brackets which were equivalent to 10  EC50 of growth (or 5  EC50 for MM
bars represent the S.D. of three biological replicates. Statistical analysis performed via
Pathogen Box compounds. *P < 0.05, **P < 0.01. No bar indicates not significant.3.5. Two inhibitors, MMV020291 and MMV006833, appear to
specifically block merozoite entry into RBCs
The eight compounds (MMV676877, MMV006833,
MMV637229, MMV020291, MMV688279, MMV687794,
MMV019721 and MMV020512) that were predicted to inhibit
invasion from the Nluc screen (six of which displayed invasion
inhibitory effects by morphological examination of Giemsa stained
smears) were tested for a direct inhibition of merozoite invasion by
performing purified merozoite invasion assays as described above.
This revealed that only one of the compounds, MMV020291,
could directly block merozoite invasion to a similar degree to that
of the heparin control (Fig. 5A). MMV637229, MMV006833 and
MMV020512 had an intermediate effect, whereas the other
compounds, MMV676877, MMV019721, MMV687794 and
MMV688279 caused negligible invasion inhibition, similar to
chloroquine (Fig. 5A).
We hypothesised that the intermediate invasion inhibitory
compounds may be exerting their invasion inhibitory effects by
causing general growth defects during the window of merozoite
egress and/or invasion. We ascertained this by measuring the
effects of compounds on other stages in the asexual lifecycle.
Whilst activity against ring-stage parasites (4–8 h post invasion),
was a criterion for elimination in compound triaging from the
screen, it was possible that these compounds may be active at
other stages. Therefore, trophozoites (~24 h post invasion) were
exposed to the lead compounds at 10  EC50 of growth for 4 h
before being washed out and allowed to proceed to the following
cycle, where they were assessed for growth via Nluc activity. It
was found that five of the invasion inhibitory compounds
(MMV676877, MMV637229, MMV688279, MMV019721 and
MMV020512) and one of the egress inhibitors (MMV016838),
decreased trophozoite growth with invasion inhibitors
MMV637229 and MMV688279 causing a significant reduction in
growth compared with control compound heparin (Fig. 5B). Thism falciparum merozoite invasion assays demonstrates one of the eight invasion
lock merozoite invasion into red blood cells (RBCs) to a similar degree as heparin.
ects whereas the remaining compounds have little effect. (B) Growth of trophozoite
compounds (MMV688279, MMV637229, MMV016838) reduce trophozoite growth
l compound, heparin. Pathogen Box compounds were tested at concentrations (lM),
V637229*) or lg/mL for heparin. Values have been normalised to 0.1% DMSO. Error
one-way ANOVA in GraphPad Prism between chloroquine (A) and heparin (B) and
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assay which demonstrated that not all of these compounds specif-
ically block merozoite invasion, thereby alluding to inhibitors that
affect general processes in the parasite that may be required at the
time of invasion. As MMV020291 and MMV006833 did not inhibit
trophozoite growth and demonstrated invasion inhibitory activity
in the purified merozoite invasion assay, we next investigated
which stage of invasion was being blocked by these compounds.
3.6. Live cell imaging of the two lead invasion inhibitors, MMV020291
and MMV006833, indicate MMV020291 blocks successful merozoite
invasion of RBCs and MMV006833 slows down the invasion process,
arresting ring formation
In order to gain an understanding of which stage of invasion
might be affected by MMV020291 and MMV006833, we assessed
the kinetics and physical morphology of P. falciparum invasion of
RBCs by live cell microscopy using methods that had been previ-
ously developed (Weiss et al., 2015) (Supplementary Videos S3–
S5). For consistency we used the same Hyp1-Nluc 3D7 parasite line
as the invasion screen, with 0.1% DMSO as the vehicle control
where we filmed and analysed 10, 11 and 12 egress events for
MMV020291, MMV006833 and DMSO treatment, respectively.
After each schizont rupture, in the presence of 10 mM
MMV020291 or 2 mM MMV006833 (~10  EC50), the number of
merozoites which adhered to neighbouring RBCs for 2 s per
egress was comparable to DMSO (DMSO mean: 24.0 merozoites,
MMV020291 mean: 25.3 merozoites, MMV006833 mean: 25.3
merozoites) (Supplementary Fig. S6A). This indicated the com-
pounds had not reduced the initial adhesiveness of the merozoites
(note that merozoites may contact more than one RBC). Merozoites
that maintain contact with their target RBCs then typically proceed
to deform the surface of the RBC they attempt to invade. The time
of initial merozoite contact to start of RBC deformation and dura-
tion of deformation upon MMV020291 treatment was comparable
to the DMSO control (Fig. 6Ai, Supplementary Fig. S6B). In contrast,
MMV006833 significantly delayed the ability of the merozoite to
induce RBC deformation but did not affect the duration of deforma-
tion (Fig. 6Ai, Supplementary Fig. S6B).
Next, the degree of RBC deformation caused by merozoite con-
tact following compound treatments was scored to assess
receptor-ligand interactions during early stages of P. falciparum
invasion of RBCs where the intensity of RBC deformation is posi-
tively correlated with successful invasion (Weiss et al., 2015).
Merozoite contact with no RBC deformation was scored as ‘zero’
and strong deformation with the merozoite wrapping the RBC
around itself was scored ‘three’ with intermediate effects scoring
‘one’ and ‘two’ (Weiss et al., 2015). In the presence of
MMV020291 there was a significant decrease in the deformation
score whilst the degree of deformation remained unchanged with
MMV006833 treatment (Fig. 6Aii). A further qualitative observation
was that treatment with MMV020291 appeared to reduce gliding
motility of the merozoites across the RBC surface (Supplementary
Video S6, DMSO and Supplementary Video S7, MMV020291).
Although MMV020291 treated merozoites appeared to attempt
to invade their target RBCs, none completed the invasion process to
achieve complete internalisation into the RBC. This is in contrast to
an average of 3.4 and 3.3 invasions per merozoite egress in the
DMSO control and MMV006833 treatments, respectively
(Fig. 6Aiii). Although, MMV006833 treated merozoites invaded,
they took significantly longer to penetrate their RBCs than the
DMSO control (14.0 s versus 10.1 s respectively, P = 0.0012,
Fig. 6Aiv).
Merozoite invasions typically cause their target RBCs to rapidly
undergo echinocytosis, a process where they develop a stellateappearance which returns to a normal biconcave shape after sev-
eral minutes, by which time the merozoite has differentiated into
a ring (Gilson and Crabb, 2009; Weiss et al., 2015). Although
MMV020291 treated merozoites did not successfully invade, they
still triggered echinocytosis in an average of 4.0 RBCs per egress.
This was not significantly different to the average 2.5 and 2.8
RBC echinocytosis events per egress in the DMSO control and
MMV006833 treatment, respectively (Supplementary Fig. S6C,
P = 0.07 (DMSO and MMV020291)).
Even though MMV020291 and MMV006833 treatment still trig-
gered RBC echinocytosis, the compounds greatly prolonged the
echinocytosis period (903.6 and 795.8, respectively) compared
with the DMSO control that saw an echinocytosis period of an
average of 404.1 seconds (Fig. 6Av). Note that the echinocytosis
periods for MMV compound treatments are an underestimate
because the echinocytosed RBCs had often not recovered their nor-
mal shape by the end of the 20 min filming period.
After invasion was complete, merozoites began to differentiate
into amoeboid, ring stage parasites several minutes later. The pro-
cess started with the growth of an arm-like projection or pseu-
dopod from the internalised merozoite before full differentiation
into an amoeba. In the DMSO control, ring conversion was com-
pleted in most invasions within 1 min (Fig. 6Avi, Supplementary
Video S3, black arrow), whereas ring formation appeared to be
greatly slowed down or even arrested with MMV006833 treatment
(mean: 803.9 s, Fig. 6Avi, P < 0.0001, Supplementary Video S5,
black arrows). The time taken for ring formation after
MMV006833 treatment was an underestimate of the severity of
the defect, since the 20 min filming period frequently ended before
ring formation was complete.
After echinocytosis had commenced following MMV020291
treatment, pseudopodial protrusions began to appear on the out-
side of RBCs where the merozoites had failed to invade (Fig. 6B).
Here, 100% of egress events and stalled invasions produced protru-
sions on at least one RBC, with a maximum of eight different RBCs
developing protrusions after a single egress event (Fig. 6Avii). This
is probably an underestimate of the pseudopod formation since
many of the merozoite contacted RBCs had more than one protru-
sion. The formation of pseudopods from failed invasions was also
occasionally observed with merozoites treated with DMSO and
MMV006833, where 16.6% and 9.1% of egress events produced a
single protrusion on the surface of a single RBC, respectively
(Fig. 6Avii).
To gain an indication that the pseudopods formed from
MMV020291 blocked invasions were equivalent to the forma-
tion of pseudopods during ring formation, we compared the
duration of echinocytosis to pseudopodia formation for
MMV020291 with DMSO and MMV006833 treatments. Here,
no significant difference was observed (Fig. 6Aviii, DMSO mean:
324.2 s, MMV020291 mean: 261.0 s, MMV006833 mean:
332.0 s), indicating that the protrusions formed after
MMV020291 treatment might emanate from merozoites that
had begun to differentiate into rings on the outside of the RBCs
they had failed to invade.
In order to confirm that these pseudopods observed after
MMV020291 treatment were parasite-derived, rather than origi-
nating from the RBC, purified schizonts and RBCs were stained
with fluorescent green and red bodipy membrane dyes, respec-
tively. This revealed that the MMV020291 induced pseudopods
were red and therefore merozoite derived, either as a result of cell
lysis or aberrant differentiation into ring-like parasites at the RBC
surface following invasion failure. The fluorescent green RBC dye
also revealed a distinct circular or ‘‘punctate structure” at the
RBC invasion site, possibly originating from failed PV formation
(Fig. 6C, white arrows).
Fig. 6. Live cell microscopy reveals MMV020291 blocks Plasmodium falciparum merozoite invasion and MMV006833 significantly slows down the invasion process and
arrests conversion into ring stages. (A) (i) Analysis performed on live cell microscopy videos of parasites treated with 10 mM MMV020291 and 2 mM MMV006833
demonstrated an increase in the time taken for MMV006833 treated merozoites to cause deformation in the red blood cell (RBC) membrane after first contact compared with
vehicle control, 0.1% DMSO. (ii) MMV020291 treated merozoites markedly lacked the ability to deform RBC membranes compared with DMSO. (iii) MMV020291 revealed
complete inhibition of merozoite invasion in contrast to DMSO and MMV006833 successful invasions. (iv) MMV006833 treated merozoites significantly increased the time
taken from initialisation of the invasion event until complete internalisation within the RBC. (v) Treatment of merozoites with both invasion inhibitory lead compounds lead
to significant prolonging in the duration of RBC echinocytosis. (vi) MMV006833 caused a significant increase in the time taken from the start of ring formation to completion.
(vii) MMV020291 caused a significant number of protrusions to form at site of merozoite contact with target RBCs after egress events occurred. (viii) There were no
differences observed between time taken from echinocytosis to pseudopodia formation for both DMSO and MMV006833 treatment after merozoite invasion, and time taken
from echinocytosis to external pseudopodia formation on the RBC surface with MMV020291 treatment. (B) Frame of a live cell microscopy video showing a ruptured schizont
treated with 10 mMMMV020291 and the merozoites that attempted but could not complete invasion, which formed protrusions extending from the point of contact with the
RBC (black arrows) (Supplementary Video S4). (C) Brightfield and fluorescence images of failed merozoite invasions following 10 mM MMV020291 treatment. The RBCs were
stained with BODIPY FL C12- Sphingomyelin (green) and the merozoites with BODIPY TR ceramide (red) which demonstrated the protrusions were derived from merozoite
material. A green ‘‘punctum” was also sometimes observed on the RBC at the site of merozoite contact (white arrow heads). Schizont rupture events (12, 10 and 11) were
filmed and analysed for DMSO, MMV020291 and MMV006833 treatment, respectively. Images and videos were analysed using ImageJ. Statistical analysis were performed on
GraphPad Prism using unpaired t tests (Ai, iii-viii) and Chi-square contingency (Aii). No bar indicates not significant. EC, echinocytosis. #. number. Scale bars indicate 5 mm.
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In this study, we have shown that by using the bioluminescent
reporter protein, Nluc, it was possible to effectively screen com-
pound libraries for inhibitors of parasite egress and invasion of
RBCs in a microplate-based manner. Using this technique, we
screened the MMV Pathogen Box and identified 15 compounds
that inhibit parasite egress and 24 invasion-specific inhibitory
compounds. We independently sourced 11 of these compounds
and investigated their activity on P. falciparum using various
growth and invasion assays, in addition to live cell microscopy.
After performing these validation assays, we grouped these
compounds into one of five following categories; (1) blockers of
late schizont maturation (MMV011765, MMV016838), (2) inhibi-
tor of the breakdown of the iRBC membranes and merozoite egress
(MMV676881), (3) direct blocker of merozoite invasion of RBCs
(MMV020291), (4) inhibitor of the invasion process and ring devel-
opment (MMV006833) and (5) general growth inhibitors that have
a strong effect on invasion (MMV676877, MMV637299,
MMV688279, MMV687794, MMV019721, MMV020512) (Fig. 7).
Using brightfield microscopy, the three Pathogen Box egress
inhibitors induced phenotypes resembling treatment with E64
and C1, compounds that target cysteine proteases and PKG, respec-
tively. PfPKG has been shown to be a master regulator of egress by
sitting at the top of a cascade of events that culminate in merozoite
release (Taylor et al., 2010; Hopp et al., 2012; Collins et al., 2013).Fig. 7. Summary of key effects of hit compounds that inhibit egress and invasion. Schem
Box compounds act to inhibit egress and invasion. MMV011765 and MMV016838 act to
cGMP dependent protein kinase G (PKG) inhibitor, Compound 1 (C1) (1). MMV676881 in
similarly to the protease inhibitor, E64 (2). MMV020291 blocks merozoite invasion by inh
slows down the invasion process, prevents RBC echinocytosis recovery and blocks ring f
and MMV688279 do not specifically block merozoite invasion or egress but may induceTreatment of schizonts with MMV011765 and MMV016838
induced a developmental arrest of merozoites that was indistinct
from each other, indicating an early stage of maturation was hin-
dered, as seen in C1-treated schizonts. However, MMV011765
appears to be irreversible suggesting that this compound perma-
nently binds to its target, prevents a time sensitive event that can-
not be resumed in order to produce viable merozoites or may be
retained intracellularly despite wash-out attempts. In a recent
screen of the Pathogen Box for T. gondii inhibitors, MMV011765
was identified as one of eight compounds in the Pathogen
Box with activity against T. gondii tachyzoites (Spalenka et al.,
2018). Identifying the target of MMV011765 may provide further
knowledge into the complex signalling mechanisms underlying
egress of apicomplexan parasites. The egress inhibitory compound,
MMV676881, was originally identified by the Nluc screen as a
putative invasion inhibitor since the Nluc enzyme was released
from the schizonts, suggesting that schizont rupture had occurred.
Giemsa stained smears, however, revealed the compound trapped
merozoites inside unruptured iRBCs. We observed that the broad-
spectrum cysteine protease inhibitor, E64, acts similarly to
MMV676881 in the Nluc invasion assay by not preventing Nluc
release. A probable explanation for the misclassification of
MMV676881 is that the RBC membrane had become leaky to the
Nluc reporter protein in mature schizonts, allowing it to escape
into the growth medium. This agrees with findings that demon-
strate RBCs are permeable to small molecules, including Nlucatic of proposed locations where Medicines for Malaria Venture (MMV) Pathogen
inhibit Plasmodium falciparum schizont maturation, resembling treatment with the
duces the formation of red blood cell (RBC) membrane-trapped merozoites, acting
ibiting penetration and prevents RBC recovery from echinocytosis (3). MMV006833
ormation (4). MMV676877, MMV019721, MMV637229, MMV020512, MMV687794
growth defects that indirectly hinder the invasion process (5).
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(Glushakova et al., 2010; Collins et al., 2013; Hale et al., 2017;
Absalon et al., 2018).
MMV676881 likely targets cysteine proteases as it was origi-
nally identified as an inhibitor of cruzain, a papain-like cysteine
protease present in Trypanosoma cruzi (Mott et al., 2010; Veale,
2019). Cysteine proteases have been shown to be crucial for mero-
zoite egress in P. falciparum through the use of E64 (Glushakova
et al., 2009), as well as genetic manipulations of cysteine proteases
such as serine rich antigen 6 (SERA6) whereby a conditional knock-
down revealed it was essential for RBC membrane rupture of sch-
izonts by reducing cytoskeletal stability (Glushakova et al., 2009;
Thomas et al., 2018). Live cell microscopy and functional assays
performed in this study indicated MMV676881 potentially acted
as a P. falciparum cysteine protease inhibitor since the RBCM
trapped merozoites it produced could be mechanically broken to
release invasion competent merozoites.
MMV020291 and MMV006833 were the most invasion-specific
inhibitors we identified in the screen. When schizonts were treated
with MMV006833, MMV020291 or DMSO, no differences were
observed in the number of merozoites which contacted RBCs per
egress and their duration of deformation. This indicated that low
affinity early interactions mediated by MSP1 and its associated
proteins are likely to be unaffected by either compound (Boyle
et al., 2017). RBC deformation was, however, weaker with
MMV020291 treatment and did not progress to strong deforma-
tion, defined by a merozoite pushing a furrow into the RBC surface.
This indicates there may be a lack of the more intense and complex
levels of deformation mediated by EBA and PfRhs interactions
(Tham et al., 2015; Koch et al., 2017). These observations are con-
sistent with MMV020291 inhibiting the discharge of micronemes
and/or rhoptries (Singh et al., 2010; Cowman et al., 2012).
In addition to the lack of extreme deformation, merozoites trea-
ted with MMV020291 did not appreciably migrate across the sur-
face of the RBC, a behaviour known as gliding motility that has
been observed in normal merozoite-RBC interactions (Weiss
et al., 2015; Perrin et al., 2018). The actin-myosin motor is critical
for deformation, motility and RBC penetration whereby merozoites
treated with actin polymerisation inhibitor, cytochalasin D, have
prevented migration over RBCs and failure of invasion (Miller
et al., 1979; Weiss et al., 2015). MMV020291 could therefore be
inhibiting the actin-myosin motor, although some functionality
must be retained since many merozoites were seen to push into
the RBC at the point at which echinocytosis began within the time-
frame of normal invasion and were also observed to partially form
a PV.
Although MMV020291 appears to inhibit strong RBC deforma-
tion, a function mediated by EBAs and PfRhs, it does not appear
to inhibit the downstream-acting PfRh5. This protein is the only
non-redundant PfRh and binds to the RBC receptor, basigin, that
probably activates secretion of the RON complex to enable
AMA1-RON2 tight junction formation (Crosnier et al., 2011; Chen
et al., 2014; Weiss et al., 2015). Antibodies to PfRh5, or basigin,
inhibit merozoite invasion but pre-invasion, deformation and
reorientation processes remain unaffected (Weiss et al., 2015,
2016). This is not what we observed following MMV020291 treat-
ment suggesting PfRh5 functions are not the target. PfRh5 inhibi-
tion also prevents echinocytosis from occurring, suggesting
MMV020291 also functions downstream of this protein since
echinocytosis clearly occurs following MMV020291 treatment. In
this respect, MMV020291 more closely mimics the effects of block-
ing the AMA1 and RON complex interaction, where merozoites
remain attached after echinocytosis was initiated and RBC recovery
to its normal biconcave shape was greatly delayed (Yap et al.,
2014; Weiss et al., 2016). MMV020291 therefore inhibits a rangeof early and late acting invasion functions making it unclear what
the possible target may be.
We observed MMV020291 treated merozoites had formed pro-
trusions at the site of contact with the RBC surface. These protru-
sions were stained with the same fluorescent dye that was used
to label the merozoites, indicating that they originated from para-
site material. These protrusions may therefore be merozoites that
have differentiated into ring-stage parasites on the outside of the
RBC as newly invaded merozoites often produce mobile, pseudopo-
dial extensions within the iRBC prior to ring differentiation which
can be observed in a normal invasion event in Supplementary
Video S3. Live cell microscopy of failed invasion events have not
been previously described to form protrusions as recently observed
with PKA and adenylate cyclase beta gene disruptions (Patel et al.,
2019). Further support that MMV020291 treatment causes unsuc-
cessful merozoites to differentiate into rings is that there was no
significant difference observed between the time taken for pseu-
dopod formation to become visible on the surface of
MMV020291 treated RBCs compared with normally invaded RBCs.
The small, partially formed PV-like structure that was visible in
some of the failed invasion sites of MMV020291 treated mero-
zoites indicates parasite-induced modification of the RBC surface
had occurred. These PV-like structures could be the equivalent of
the whorl-like membranous structures that have been seen to form
at the RBC surface from rhoptry contents when merozoite invasion
was arrested with cytochalasin D (Riglar et al., 2011).
In contrast to MMV020291, MMV006833 treatment did not
affect the ability of the merozoite to deform RBCs, form tight junc-
tions and invade RBCs, indicating that the release of the rhoptries,
micronemes and associated interactions with RBC receptors were
unaffected. Whilst MMV006833 treated merozoites were able to
fully enter their RBCs, the invasion process was significantly slower
than normal invasion events, suggesting that the actin-myosin
motor may be affected. However, treatment with MMV006833
did not affect the ability of the merozoite ability to cause severe
deformation, which indicates that the actin-myosin motor can still
function, as treatment with cytochalasin D has previously been
shown to block deformation (Weiss et al., 2015). Once invaded,
the merozoites treated with MMV006833 were observed to arrest
in at the pseudopod stage, unable to differentiate into ring-stage
parasites, and this may be the mechanism by which this compound
blocks growth. There is little known about the mechanisms under-
lying merozoite differentiation into ring stage parasites post inva-
sion and identifying the target of MMV006833 may further the
study of this process.
The remaining six compounds (MMV676877, MMV637229,
MMV688279, MMV687794, MMV019721 and MMV020512) from
the lead list we have termed ‘‘general growth inhibitors” as whilst
they inhibited schizont progression to ring-stage parasites in the
primary Nluc screen, did not specifically block parasite invasion.
This was corroborated by growth assays that determined five out
of six of these compounds have inhibitory activity across other
stages of the lifecycle (MMV676877, MMV637229, MMV688279,
MMV019721 and MMV020512). Supporting this, a screen of the
MMV Pathogen Box to identify stages of compound activity in
the P. falciparum RBC 48 h lifecycle by using DNA content as a mar-
ker of stage arrest, classified these five compounds as either arrest-
ing parasite growth without DNA replication (i.e. ring stage) or
halting growth at trophozoite stage without sufficient DNA replica-
tion (Tougan et al., 2019). It is therefore likely that some of these
compounds could disrupt general cellular pathways such as DNA
regulation or transcription and translation machinery. It has been
demonstrated in schizonts that 10% of the parasite genome has a
high level of transcription, with genes encoding for proteins such
as MSPs, and rhoptries being upregulated in late schizogony
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primary Nluc screen targeting elongation factor 2 (EF2) and DNA
binding agents were removed for possessing ring stage activity
and lacking novel targets in the compound triaging process
(Rodríguez et al., 2008; Baragaña et al., 2015; Duffy et al., 2017).
This demonstrates that agents that block DNA regulation may
inadvertently inhibit essential invasion genes from being tran-
scribed, thereby inducing invasion inhibitory phenotypes. Whilst
an in silico analysis of potential molecular docking candidates to
PfCDPK5 identified MMV020512 as a hit compound (Rout and
Mahapatra, 2019), we have failed to observe any inhibitory pheno-
types that have previously been seen with PfCDPK5 knockdowns,
namely the development of RBCM trapped merozoites (Dvorin
et al., 2010; Absalon et al., 2018).
The sixth of these general growth inhibitors, MMV687794, was
identified as an inhibitor that arrested late trophozoite/schizont
after DNA replication occurred in the aforementioned study
(Tougan et al., 2019) and whilst it did not directly inhibit invasion
in the purified merozoite assays, we saw no growth defects at
other stages. This could indicate that this compoundmay block tar-
gets upstream of invasion that are required to ‘‘prime” the mero-
zoite for invasion in the schizont stage, such as proteins that
undergo proteolytic processing in schizonts such as AMA1, MSP1
and the rhoptry associated protein, RAP1 (Howard et al., 1998;
Baldi et al., 2000; Silmon de Monerri et al., 2011; Das et al.,
2015; Nasamu et al., 2017; Pino et al., 2017).
In conclusion, we have identified three specific merozoite
egress, one RBC invasion inhibitor and one inhibitor that slows
invasion and arrests ring development, in addition to several other
general growth inhibitors that strongly act during the invasion
stages. These inhibitors, together with their novel mechanisms of
action, could complement current antimalarials which generally
act on intracellular parasites during their growth phase. It will be
important to identify the target proteins of the egress and invasion
inhibitor compounds because this will inform structure–activity
relationship based drug design to improve the potencies of
compounds. Once their targets are known, these compounds could
also act as useful tools to further dissect molecular details of egress
and invasion processes in the parasite.
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